Page last updated: 2024-11-04

ropinirole and Mental Disorders

ropinirole has been researched along with Mental Disorders in 8 studies

Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.

Research Excerpts

ExcerptRelevanceReference
") and restless legs syndrome treated with ropinirole and gabapentin, will be discussed."4.89Recent advances in sleep research. ( Anderer, P; Saletu, B; Saletu-Zyhlarz, GM, 2013)
"Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parkinson's disease."2.43Ropinirole, a non-ergoline dopamine agonist. ( Angersbach, D; Jost, WH, 2005)
"Japanese encephalitis is a cause of substantial morbidity and mortality, prevalent mainly in South East nations."1.38Bilateral facial palsy as a manifestation of Japanese encephalitis. ( Praharaj, HN; Verma, R, 2012)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amos, LB1
Grekowicz, ML1
Kuhn, EM1
Olstad, JD1
Collins, MM1
Norins, NA1
D'Andrea, LA1
Saletu, B1
Anderer, P1
Saletu-Zyhlarz, GM1
Pagonabarraga, J2
Kulisevsky, J2
Pérez-Pérez, J1
Martínez-Horta, S1
Fernández-Bobadilla, R1
Sierra, S1
Pascual-Sedano, B1
Gironell, A1
Verma, R1
Praharaj, HN1
Klos, KJ1
Bower, JH1
Josephs, KA1
Matsumoto, JY1
Ahlskog, JE1
Stocchi, F1
Jost, WH1
Angersbach, D1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance[NCT02882880]51 participants (Actual)Interventional2015-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for ropinirole and Mental Disorders

ArticleYear
Recent advances in sleep research.
    Psychiatria Danubina, 2013, Volume: 25, Issue:4

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Amines; Antiparkinson Agents; Biomedical Research;

2013
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
    Revista de neurologia, 2014, Jan-01, Volume: 58, Issue:1

    Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-

2014
Ropinirole, a non-ergoline dopamine agonist.
    CNS drug reviews, 2005,Autumn, Volume: 11, Issue:3

    Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Humans; Indoles; Mental Disorde

2005

Other Studies

5 other studies available for ropinirole and Mental Disorders

ArticleYear
Treatment of pediatric restless legs syndrome.
    Clinical pediatrics, 2014, Volume: 53, Issue:4

    Topics: Adolescent; Amines; Analgesics; Anticonvulsants; Antioxidants; Benzothiazoles; Child; Child, Prescho

2014
Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Drugs & aging, 2015, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Apathy; Benzothiazoles; Cross-Sectional Studie

2015
Bilateral facial palsy as a manifestation of Japanese encephalitis.
    BMJ case reports, 2012, Jul-19, Volume: 2012

    Topics: Aged; Dopamine Agonists; Encephalitis Virus, Japanese; Encephalitis, Japanese; Facial Paralysis; Fev

2012
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    Parkinsonism & related disorders, 2005, Volume: 11, Issue:6

    Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Catechols; Databases, Factual; Dopamine Agonists;

2005
Pathological gambling in Parkinson's disease.
    The Lancet. Neurology, 2005, Volume: 4, Issue:10

    Topics: Antiparkinson Agents; Benzothiazoles; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Ga

2005